Incyte Corporation (NASDAQ: INCY) recently received a number of ratings updates from brokerages and research firms:

  • 10/31/2017 – Incyte Corporation was given a new $135.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “hold” rating on the stock.
  • 10/31/2017 – Incyte Corporation had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/31/2017 – Incyte Corporation had its price target raised by analysts at BMO Capital Markets from $162.00 to $166.00. They now have an “outperform” rating on the stock.
  • 10/26/2017 – Incyte Corporation had its price target lowered by analysts at BMO Capital Markets from $163.00 to $162.00. They now have an “outperform” rating on the stock.
  • 10/25/2017 – Incyte Corporation had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/6/2017 – Incyte Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 10/6/2017 – Incyte Corporation is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “buy” rating and a $160.00 price target on the stock.

Shares of Incyte Corporation (NASDAQ:INCY) traded down $2.09 during trading on Wednesday, hitting $105.12. The stock had a trading volume of 1,968,500 shares, compared to its average volume of 1,944,177. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. Incyte Corporation has a twelve month low of $98.49 and a twelve month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. During the same quarter in the prior year, the firm posted $0.19 earnings per share. The company’s revenue was up 41.6% on a year-over-year basis. equities analysts anticipate that Incyte Corporation will post -1.3 earnings per share for the current fiscal year.

In other news, EVP Steven H. Stein sold 2,111 shares of the company’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $125.00, for a total transaction of $263,875.00. Following the completion of the sale, the executive vice president now directly owns 18,687 shares of the company’s stock, valued at $2,335,875. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Eric H. Siegel sold 1,820 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $137.40, for a total value of $250,068.00. Following the sale, the executive vice president now directly owns 23,553 shares of the company’s stock, valued at $3,236,182.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,062 shares of company stock valued at $12,652,893. 17.70% of the stock is currently owned by company insiders.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.